Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.

ABSTRACT:

Objective

We aimed to compare the potential for inducing HIV production and the effect on T-cell activation of potent HDAC inhibitors undergoing clinical investigation.

Design

In vitro study

Results

The various HDAC inhibitors displayed significant potency differences in stimulating HIV-1 expression from the latently infected cell lines with panobinostat>givinostat ≈belinostat>vorinostat>valproic acid. Panobinostat was significantly more potent than all other HDAC inhibitors and induced virus production even in the very low concentration range 8-31 nM. The proportion of primary T-cells expressing the early activation marker CD69 increased moderately in all HDAC inhibitor-treated cells compared with untreated cells. Finally, proof was obtained that panobinostat, givino

SUBMITTER: Rasmussen TA 

PROVIDER: S-EPMC3899169 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature